Bio-Research.AI

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/18 Verastem Oncology's RAMP 203 phase 1/2 study reports no dose-limiting toxicities in avutometinib, sotorasib, and defactinib combination for KRAS G12C mutant NSCLC 12/18 Cognition Therapeutics, Inc.'s phase 2 'SHIMMER' Study Demonstrates Safety and Tolerability of CT1812 for Dementia with Lewy Bodies Patients Over Six Months 12/18 CorestemChemon Inc.'s phase 3 Clinical Trial Fails to Achieve Primary Endpoint for Neuronata-R Injection in ALS Patients Over 12 Months 12/18 ALK Advances Peanut Allergy Treatment Tablet to phase II Following Satisfactory Phase I/II Safety Results 12/17 Hansa Biopharma's phase 2 Trial of Imlifidase Shows Improvement in GBS Patients, Accelerates Return to Independent Walking by Six Weeks 12/17 Aurion Biotech's phase 1/2 Trial of AURN001 Shows Significant Improvement in Corneal Edema Treatment with No Serious Ocular Adverse Events Reported [Deals] 12/18 Cara Therapeutics and Tvardi Therapeutics to Merge and Develop Novel STAT3 Inhibitor Treatments 12/18 Photys Therapeutics and Novo Nordisk Partner to Develop Cardiometabolic Disease Therapeutics, Deal Worth up to $186M 12/18 Inceptor Bio and Grit Biotechnology form strategic partnership for clinical development of CAR-T therapy, IB-T101, in China 12/18 Merck and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. strike a $112M upfront deal with potential $1.9B in milestones for global HS-10535 license agreement 12/17 Theranexus and Exeltis ink EUR 2M deal for TX01, targeting Gaucher and Niemann-Pick type C diseases with potential for additional milestone payments [Venture Capital] 12/18 SiteOne Therapeutics, Inc. secures $100 million financing to advance sensory hyperexcitability disorder treatments [Regulatory] 12/18 European Commission grants orphan medicinal product designation to Agios Pharmaceuticals' mitapivat for sickle cell disease treatment 12/18 FDA grants Orphan-Drug Designation to MediLink Therapeutics's YL201 for small cell lung cancer treatment 12/17 FDA grants Breakthrough Therapy Designation to Gilead Sciences's Trodelvy following TROPiCS-03 study results same day : ( ↑ NASDAQ: GILD | +0.79% ) 12/17 FDA approves Celltrion Inc's STEQEYMA for adult and pediatric plaque psoriasis, others based on phase III study results 12/17 Eli Lilly's Kisunla approved in China for early symptomatic Alzheimer's patients based on TRAILBLAZER-ALZ 2 phase 3 clinical study results View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/17 Actuate Therapeutics, Inc. reports increased survival rates in phase 2 trial of elraglusib with GnP in metastatic pancreatic ductal adenocarcinoma 12/17 Biomea Fusion Reports Significant Reduction in HbA1c in Diabetes Patients Through 26-Week COVALENT-111 Study Using Icovamenib 12/17 Regeneron's phase 3 Trial of EYLEA HD Injection for Retinal Vein Occlusion-related Macular Edema Meets Primary Endpoint 12/17 Sanofi and Teva Pharmaceuticals' phase 2b RELIEVE UCCD study of duvakitug meets primary endpoints in ulcerative colitis and Crohn's disease patients 12/16 UCB's ORCHESTRA Study of Minzasolmin Fails to Meet Primary and Secondary Endpoints in Early Parkinson’s Disease Trials [Deals] 12/17 MilliporeSigma to Acquire HUB Organoids Holding B.V., Solidifying Position in Cell Culture Portfolio and Advancing Drug Development 12/17 Silexion Therapeutics Corp and Evonik Collaborate on Advanced siRNA Formulation, SIL-204, Targeting KRAS Mutations in Cancer Treatment 12/17 Orexo AB publ and Abera Bioscience AB collaborate to develop intranasal vaccines using AmorphOX technology and funding from CEPI 12/17 SK Biopharmaceuticals and ProEn Therapeutics collaborate to develop radiopharmaceutical candidates using ArtBody™ platform by 2027 12/17 Akamis Bio Partners with Xuanzhu Biopharmaceutical Co., Ltd. for the Licensing of Oncology Candidate NG-350A in Greater China 12/17 Gilead Sciences and Terray Therapeutics form strategic partnership for AI-driven drug discovery using tNova platform 12/16 Nona Biosciences and Candid Therapeutics Collaborate on $320M Agreement for T-cell Engagers Discovery in Autoimmune Diseases 12/16 Scailyte and Visterra Inc. collaborate to use AI in accelerating development of autoimmune disease treatments [Venture Capital] 12/17 Akamis Bio secures $60 million in Series A Prime financing and strategic partnership for NG-350A clinical trials in advanced rectal cancer 12/16 Concinnity Genetics secures £3m funding to advance gene control systems development for cell and gene therapy market [Regulatory] 12/17 EyeDNA Therapeutics' HORA-PDE6b therapy for inherited retinal dystrophy earns Rare Pediatric Disease Designation from US FDA 12/17 FDA Accepts Merck's Biologics License Application for Clesrovimab, Long-Acting Monoclonal Antibody for RSV Disease Prevention in Infants 12/17 FDA Fast Tracks Lipocine Inc.'s LPCN 1148 for Sarcopenia in Patients with Decompensated Cirrhosis View the full newsletter contents for free via the link in the comments.

#56% RR of IGF-1 Mab in TED #SMARCA2/SMARCA4 Inhibitor Stop #T-cell Engager 1B Deal #Big pharma OSA Treatment Deal [Clinical Trials] 12/16 Edgewise Therapeutics Reports Primary Endpoint Met with 28% Reduction in CK Levels in Phase 2 CANYON Trial for Becker Muscular Dystrophy 12/16 MENARINI Group and NewAmsterdam Pharma Corporation Report Phase 3 BROADWAY and TANDEM Results with Obicetrapib Achieving 33% LDL-C Reduction and Combo with Ezetimibe 48.6% 12/16 Foghorn Therapeutics Inc. Stops Development of Leukemia Drug FHD-286, Shifts Focus to SMARCA2 Inhibitor FHD-909 12/16 Viridian Therapeutics, Inc.' THRIVE-2 phase 3 trial for veligrotug meets all endpoints in Chronic Thyroid Eye Disease, with a 56% Proptosis Responder Rate at Week 15 [Deals] 12/16 Bavarian Nordic and Serum Institute of India Pvt. Ltd. strike licensing and manufacturing agreement for MVA-BN® mpox vaccine 12/16 Mochida Pharmaceutical grants Kuhnil Pharmaceutical, Co. Ltd. exclusive rights for development and marketing of Epadel in South Korea same day : ( ↑ JPX: 4534 | +0.14% ) 12/16 Innoviva and Basilea Pharmaceutica Enter into $4M Agreement for Commercialization of MRSA Treatment, Zevtera, in the US same day : ( ↑ SIX: BSLN | +6.33% ) 12/16 Candid Therapeutics Teams Up with EpimAb Biotherapeutics, Inc. in $1B Deal to Develop T-cell Engager Program Candidates 12/15 Innovent Biologics to Handle Commercialization of Eli Lilly and Company's Cancer Drug Jaypirca® in Mainland China Following New Agreement 12/13 KYORIN Pharmaceutical Co., Ltd. Secures Global Rights for Bayer's Obstructive Sleep Apnea Treatment BAY2925976 in €15M Deal with Up to €70M in Potential Milestones same day : ( ↓ XETR: BAYN | -2.06% ) ( ↓ JPX: 4569 | -1.09% ) 12/13 AbbVie to Acquire Nimble Therapeutics for $200M, Gaining Oral Peptide IL23R Inhibitor and Peptide Synthesis Platform same day : ( ↑ NYSE: ABBV | +0.1% ) [Venture Capital] 12/16 Promise Bio Secures $8.3 Million Seed Investment for Computational Platform Development in Drug Research View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/13 Akeso's phase III HARMONi-A Study Shows Ivocitinib Reduces Disease Progression or Death Risk by 56% in NSCLC Patients 12/13 Incyclix Bio Releases Interim Results from phase 1/2 Trial of INX-315 for CDK4/6 Inhibitor-Resistant Cancer 12/13 Alphamab Oncology Reports phase II Clinical Study Results for KN046-Axitinib Combination in Advanced NSCLC Treatment 12/12 Keros Therapeutics Pauses TROPOS phase 2 Clinical Trial of Cibotercept for PAH due to Unanticipated Adverse Events same day : ( ↓ NASDAQ: KROS | -73.04% ) 12/12 RemeGen Biosciences' phase III Study Shows Disitamab Vedotin Improves Progression-Free Survival in HER2-Positive Advanced Breast Cancer Patients with Liver Metastasis 12/12 Pfizer Announces Improved Progression-Free Survival in Breast Cancer Patients with IBRANCE: phase 3 PATINA Trial Results 12/12 Bicycle Therapeutics Reveals Data on Zelenectide Pevedotin Efficacy in Breast Cancer Trials and Combative Action in Metastatic Urothelial and Lung Cancer [Deals] 12/13 EA Pharma Strikes €117M Licensing Deal with Newron for Schizophrenia Drug Evenamide in Japan and Selected Asian Markets same day : ( ↑ SIX: NWRN | +16.88% ) ( ↑ XETR: NP5 | +19.19% ) 12/13 Dx & Vx Licenses OVM-200 from OXFORD VACMEDIX UK LIMITED for Development and Commercialisation in Asia, Oxford to Receive Milestone Payments and Royalties 12/12 General Inception General Inception acquires Enable Medicine to boost drug discovery by leveraging AI-powered biological data platform 12/12 BeiGene Lands $150M Global Licensing Deal With CSPC for SYH2039, a MAT2A-Inhibitor Targeting MTAP-Deleted Solid Tumors same day : ( ↓ NASDAQ: BGNE | -2.23% ) [Venture Capital] 12/12 Turn Therapeutics secures $75 million investment from GEM Global for further healthcare research [Regulatory] 12/13 Seladelpar Receives European Medicines Agency Committee Recommendation for Primary Biliary Cholangitis Treatment Following FDA Endorsement 12/13 Geron Corporation's RYTELO recommended for approval by EMA's Committee for treatment of specific transfusion-dependent anemia types 12/13 CHMP Recommends Acoramidis for Marketing Authorization in EU for ATTR-CM Treatment same day : ( ↓ XETR: BAYN | -0.52% ) ( ↓ XETR: BAYN | -0.52% ) 12/13 Merck's WELIREG recommended by European Medicines Agency's CHMP for conditional approval in treating VHL disease and RCC based on phase 2 and 3 trial data 12/13 FDA grants Breakthrough Therapy designation to tolebrutinib for secondary progressive multiple sclerosis treatment based on HERCULES phase 3 study results 12/13 EMA approves Vabysmo for the treatment of various vision loss conditions following US FDA approval in July 2024 same day : ( ↓ SIX: ROG | -0.71% ) 12/13 CHMP endorses nemolizumab for atopic dermatitis and prurigo nodularis treatments following successful phase III trials View the full newsletter contents for free via the link in the comments.

[Clinical Trials] 12/12 Blue Lake Biotechnology's BLB201 intranasal vaccine shows over 80% reduction in symptomatic RSV infections in phase 1/2a study 12/11 AnaptysBio Halts Investment in ANB032 After Failing Primary and Secondary Endpoints in Atopic Dermatitis Global Trial same day : ( ↓ NASDAQ: ANAB | -32.83% ) 12/11 Expression Therapeutics, Inc. Lentiviral Gene Therapy Achieves Zero Annual Bleeding Events in Hemophilia A Patients with Undetectable to Therapeutic Factor VIII Levels in phase 1 Trial of ET3 for Hemophilia A 12/11 Corcept Therapeutics phase 2 DAZALS Trial Fails to Meet Primary Endpoint, Observation of Gastrointestinal Upsets Increase in Dazucorilant Patients [Deals] 12/12 Neuraxpharm Partners with Pharmathen to Develop and Distribute Long-Acting Treatments for CNS Disorders 12/12 Neurimmune AG and AICURA medical GmbH team up to leverage AI for Alzheimer's drug development 12/12 Daewoong Pharmaceutical allies with Tiolab Therapeutics, DaehanNupharm, and Dalim Biotech for 4-week long-acting obesity treatment, eyeing phase 1 clinical trials next year 12/12 Dewpoint Therapeutics partners with ConcertAI on phase 1 of Translational Oncology for DPTX3186 development, raising $287M and $230M respectively 12/12 Esperion Therapeutics Licenses NEXLETOL and NEXLIZET to Neopharm Group Israel, Getting Upfront and Milestone Payments 12/12 Elevation Oncology Licenses Synaffix BV's ADC Technology for $368M, Plans Development of HER3 Candidate EO-1022 12/11 Meitheal Pharmaceuticals, Inc. Lands Exclusive US Rights for Antibiotic XENLETA through $300M Agreement with Hong Kong King-Friend Industrial Co and Nabriva Therapeutics plc Therapeutics [Venture Capital] 12/11 Okogen, Inc. secures $3.3 million funding to aid completion of phase 2b clinical program for conjunctivitis treatment and development of AI-driven image-based evaluation platform View the full newsletter contents for free via the link in the comments.

🌟 Top 20 BioPharma Deals of 2024! 🌟 This year, the industry has been driven by groundbreaking collaborations and high-value deals. We’ve compiled the Top 20 partnerships across License Agreements, Strategic R&D Collaborations, and Option Agreements that are shaping the future of BioPharma. From 🧬 oncology to 🧠 neuroscience and 🧪 rare diseases, the industry's scope continues to expand with transformative agreements. 🏆 Top 5 Deals 1️⃣ Prime Medicine, Inc. & Bristol-Myers Squibb ($3.61B) 🔬 Prime Medicine and Bristol Myers Squibb have signed a $3.61 billion agreement to develop and commercialize next-generation ex vivo T cell therapies using Prime Editing and PASSIGE™ technologies. 2️⃣ LaNova Medicines & Merck (MSD) ($3.28B) 💊 LaNova Medicines and Merck (MSD) entered a $3.28 billion exclusive license agreement for the global development, manufacturing, and commercialization of LM-299, a bispecific antibody targeting PD-1 and VEGF. 3️⃣ Dren Bio, Inc. & Novartis ($3.00B) 🛠️ Dren Bio and Novartis Pharma have formed a $3 billion collaboration to develop bispecific antibodies for cancer treatments using Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform. 4️⃣ PTC Therapeutics, Inc. & Novartis ($2.90B) 🧠 PTC Therapeutics and Novartis Pharmaceuticals signed a $2.9 billion exclusive license agreement for the global development and commercialization of Huntington’s disease treatment PTC518. 5️⃣ Schrödinger & Novartis ($2.42B) 📊 Schrödinger and Novartis entered into a $2.42 billion research collaboration and license agreement to develop and commercialize multiple therapeutic candidates. 🔍 Stay tuned for Top M&A Deals next week! 🔍 Subscribe to Bio-Research.AI for daily BioPharma insights. ✨ Which deal or technology do you find most exciting? Share your thoughts in the comments! 💬 #Monte Rosa Therapeutics #AviadoBio #Astellas Pharma #AC Immune #Takeda #MOMA Therapeutics #Roche #ImmuneOnco_Biopharmaceuticals #Instil Bio #CSPC Pharmaceutical Group #AstraZeneca #Gilgamesh Pharmaceuticals #AbbVie #Ribocure Pharmaceuticals AB #Boehringer Ingelheim #Sangamo Therapeutics, Inc. #Genentech #Medincell #Mestag Therapeutics #Flare Therapeutics #Repertoire Immune Medicines #Ascidian Therapeutics #MediLink Therapeutics #BioNTech SE

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/11 Eli Lilly and Company's phase 3 EMBER-3 Trial Shows Imlunestrant Improves Progression-Free Survival in Advanced Breast Cancer 12/11 Candel Therapeutics Reports Improved Disease-Free Survival in phase 3 Trial of CAN-2409 for Localized Prostate Cancer 12/11 Pharming Group N.V. Group Completes phase III Trial of Lleniolisib in Pediatric APDS Patients, Plans for 2025 Regulatory Filings 12/11 Arrowhead Pharmaceuticals Reports Up to 90% Reduction in CFB Protein with ARO-CFB in phase 1/2a Study 12/10 ACELYRIN, INC. Suspends Izokibep Development for Uveitis After Failed phase 2b/3 Trial 12/10 Moberg Pharma AB's MOB-015 Fails to Meet Primary Endpoint in phase 3 North American Study [Deals] 12/11 TC BioPharm collaborates with CareDx, Inc. for phase II ACHIEVE trial assessing TCB008 in Acute Myeloid Leukemia patients 12/11 PolyPid Ltd. and ImmunoGenesis, Inc. collaborate to develop novel formulations targeting solid tumors with PLEX and STING technologies 12/11 Chroma Medicine merges with Nvelop Therapeutics to form nChroma Bio, seals $75M financing for CRMA-1001 lead program [Venture Capital] 12/11 Noema Pharma secures CHF 130 million in Series B funding for ongoing phase 2 clinical trials 12/10 Tasca Therapeutics secures $52 million for drug discovery platform and to advance CP-383 into phase 1/2 clinical trials [Regulatory] 12/11 FDA Grants Fast Track Designation to Sanofi's Dual Vaccines for Individuals Aged 50 and Over, Undergoing phase 1/2 Trials 12/11 Santhera Pharmaceuticals' AGAMREE receives approval from NMPA for Duchenne muscular dystrophy treatment in China View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/10 NewAmsterdam Pharma Corporation's phase 3 Trial Finds Obicetrapib Reduces LDL-C Levels for Cardiovascular Disease Risk Patients 12/10 CervoMed Inc. Halts phase 3 Trial Preparations for Neflamapimod in DLB Treatment Following Unmet Endpoints in Phase 2b 12/09 Eli Lilly and Company's phase 3 trial of Pirtobrutinib shows 46% reduction in risk of relapse, disease progression or death in CLL patients 12/09 TNF Pharmaceuticals, Inc. reports decrease in inflammation biomarkers in phase 2a sarcopenia trial of MYMD-1, plans phase 2b study for 2025 same day : ( ↑ NASDAQ: TNFA | +13.71% ) 12/09 GSK's DREAMM-7 Trial Shows 42% Reduction in Death Risk with BVd Combination for Multiple Myeloma Treatment same day : ( ↑ LSE: GSK | +0.69% ) [Deals] 12/10 Evariste joins hands with Orion Corporation for preclinical research to design therapeutics using AI and math 12/10 GSK and Relation Ink $45M Upfront Deal for Fibrotic and Osteoarthritis Therapies, with Potential Earn-outs Averaging $200M per Target same day : ( ↑ LSE: GSK | +0.69% ) 12/10 Ahn-Gook Pharmaceuticals forms strategic partnership with APITBIO Inc. for new antibody-based drug development 12/10 Novo Nordisk invests in Eikonizo Therapeutics for development of HDAC6 inhibitors and EKZ-102, first-in-human clinical study slated for 2025 12/09 Cimeio Therapeutics and Kyowa Kirin Co., Ltd. Ink Research Collaboration Worth up to $300M for New Disease Therapies Development same day : ( ↑ JPX: 4151 | +2.03% ) 12/09 Nona Biosciences and Kodiak Sciences collaborate for discovery of ophthalmic disease treatments using Harbour Mice® technology same day : ( ↑ NASDAQ: KOD | +29.63% ) [Venture Capital] 12/10 AQEMIA secures $38 million investment from Cathay Innovation for clinical trials preparation and drug discovery platform enhancement 12/10 Orthogon Therapeutics Raises $25M in Funding to Further Research on Antivirals for BK Virus in Transplant Patients [Regulatory] 12/09 Celltrion Inc's Omlyclo gets Health Canada | Santé Canada approval as first omalizumab biosimilar for treating chronic idiopathic urticaria, allergic asthma, chronic rhinosinusitis with nasal polyps 12/09 Cantex Pharmaceuticals, Inc. receives FDA Orphan Drug Designation for Azeliragon in treating brain metastasis from breast cancer View the full newsletter contents for free via the link in the comments.

[Clinical Trials] 12/09 Vivoryon Therapeutics N.V. phase 2 VIVA-MIND Study with Varoglutamstat Halts Early, Fails to Meet Primary and Secondary Endpoints, Reports Improved Kidney Function 12/09 Enanta Pharmaceuticals Reports phase 2 Study Results: Zelicapavir Shows Antiviral Effect and Safety in Treating Respiratory Syncytial Virus 12/09 Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. Announce High Complete Remission Rate in phase 1 AML Trial of Ziftomenib 12/09 AbbVie's phase 3 Trial of Tavapadon Shows Statistically Significant Improvements in Early Parkinson's Disease Treatment 12/09 Secura Bio, Inc. Reveals 48% Overall Response Rate in phase 2 PRIMO Clinical Trial of Duvelisib for T-Cell Lymphoma Patients 12/07 Novo Nordisk Releases 52-Week phase 2 Results on Etavopivat for Sickle Cell Disease, Observes Hemoglobin Increase at Week 24 12/07 Sanofi's phase 3 LUNA 3 Study Reports 65% Platelet Response with Rilzabrutinib in Chronic ITP Patients 12/06 BioAge Labs Halts phase 2 Study of Azelaprag due to Liver Transaminitis, Set to Re-evaluate Data and Progress NLRP3 Inhibitor Program [Deals] 12/09 Formycon AG and MS PHARMA ink deal to commercialize FYB202 biosimilar in Middle East and North Africa 12/09 FivepHusion secures exclusive option to acquire UOW's next-gen drug delivery platform ResectAssist, targeting $4B pancreatic cancer treatment market 12/09 Johnson & Johnson gains control of Mestag Therapeutics's novel target, part of multi-year agreement with potential for future payments [Venture Capital] 12/09 Citryll secures EUR 85 million Series B for clinical development of CIT-013, phase 2a trials for rheumatoid arthritis and hidradenitis suppurativa planned View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/06 Novartis' APPULSE-PNH study shows Fabhalta improves hemoglobin levels in PNH patients after 24 weeks of treatment same day : ( ↓ SIX: NOVN | -0.41% ) 12/05 Pharma Two B reveals pooled data analysis of phase 2b and phase 3 trial for P2B001's efficacy in early-stage Parkinson's disease patients 12/05 Medicenna Therapeutics Corp. Reports Complete Tumor Regression in Patients Treated with MDNA11 and KEYTRUDA in phase 1/2 ABILITY-1 Study same day : ( ↑ NYSE: MRK | +2.15% ) 12/05 MediciNova, Inc. continues phase 2b/3 ibudilast trial for ALS following interim analysis, with results expected in 2026 12/05 Duality Biologics and BioNTech SE's Clinical Trial Reveals 70.4% Response Rate in SCLC Patients Treated with BNT324/DB-1311 12/05 Daiichi Sankyo and AstraZeneca's TROP2 directed ADC shows 42.7% response rate in phase 2 and 3 trials for EGFR-mutated non-small cell lung cancer same day : ( ↓ JPX: 4568 | -3.6% ) [Deals] 12/06 Indapta Therapeutics and Sanofi collaborate to evaluate IDP-023 and Sarclisa combination for relapsed/refractory multiple myeloma treatment in amended phase 1 study 12/05 Teva Pharmaceuticals to Sell Shares of Teva Takeda Pharma and Subsidiary to JKI Co., in Pivot to Growth Strategy by 2025 12/05 Muna Therapeutics and GSK ink €173.5M deal to identify Alzheimer's drug targets using MiND-MAP platform same day : ( ↑ LSE: GSK | +0.41% ) 12/05 Aclaris Therapeutics, Inc. Enters $940M Deal with Sino Biopharmaceutical Limited and Biosion for Global Development of TSLP Antibody BSI-045B same day : ( ↑ NASDAQ: ACRS | +1.33% ) [Regulatory] 12/05 MindMed's MM120 ODT receives UK MHRA's Innovation Passport for treatment of Generalized Anxiety Disorder same day : ( ↓ NASDAQ: MNMD | -4.95% ) 12/05 FDA grants Fast Track designation for EpicentRx, Inc.'s AdAPT-001 for advanced, refractory soft tissue sarcoma treatment View the full newsletter contents for free via the link in the comments.